Skip to main content

Advertisement

SpringerLink
Log in

Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

For patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvalumab consolidation therapy, no subsequent standard treatment exists. The type of treatment selected for each timing of disease progression and its efficacy have not been investigated.

Methods

We retrospectively enrolled patients with LA-NSCLC or inoperable NSCLC that progressed after definitive CRT and durvalumab consolidation therapy at 15 Japanese institutions. Patients were classified into the following: Early Discontinuation group (disease progression within 6 months after durvalumab initiation), Late Discontinuation group (disease progression from 7 to 12 months after durvalumab initiation), and Accomplishment group (disease progression from 12 months after durvalumab initiation).

Results

Altogether, 127 patients were analyzed, including 50 (39.4%), 42 (33.1%) and 35 (27.5%) patients from the Early Discontinuation, Late Discontinuation, and Accomplishment groups, respectively. Subsequent treatments were Platinum plus immune checkpoint inhibitors (ICI) in 18 (14.2%), ICI in 7 (5.5%), Platinum in 59 (46.4%), Non-Platinum in 35 (27.6%), and tyrosine kinase inhibitor in 8 (6.3%) patients. In the Early Discontinuation, Late Discontinuation, and Accomplishment groups, 4 (8.0%), 7 (16.7%), and 7 (20.0%) patients were receiving Platinum plus ICI; 21 (42.0%), 22 (52.4%), and 16 (45.7%) were receiving Platinum, and 20 (40.0%), 8 (19.0%), and 7 (20.0%) were receiving Non-Platinum, respectively. No significant difference in progression-free survival was observed in the timing of disease progression.

Conclusion

In patients with LA-NSCLC hat progressed after definitive CRT and durvalumab consolidation therapy, subsequent treatment may change depending on the timing of disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and material

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Marino P, Preatoni A, Cantoni A (1995) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76(4):593–601. https://doi.org/10.1002/1097-0142(19950815)76:4%3c593::aid-cncr2820760409%3e3.0.co;2-n

    Article  CAS  PubMed  Google Scholar 

  2. Pritchard RS, Anthony SP (1996) Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125(9):723–729. https://doi.org/10.7326/0003-4819-125-9-199611010-00003

    Article  CAS  PubMed  Google Scholar 

  3. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190. https://doi.org/10.1200/jco.2009.26.2543

    Article  PubMed  Google Scholar 

  4. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40(12):1301–1311. https://doi.org/10.1200/jco.21.01308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Taira T, Yoshino R, Kenmotsu H, Saitoh J, Harada H, Naito T, Murakami H, Tomizawa Y, Matsuura M, Saito R, Nakajima T, Yamada M, Takahashi T (2015) Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. Springerplus 4:152. https://doi.org/10.1186/s40064-015-0929-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Giaj Levra M, Cotte FE, Corre R, Calvet C, Gaudin AF, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assie JB, Chouaid C (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer 140:99–106. https://doi.org/10.1016/j.lungcan.2019.12.017

    Article  PubMed  Google Scholar 

  7. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro CJ, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697

    Article  CAS  PubMed  Google Scholar 

  8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  9. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE—version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90–92. https://doi.org/10.1016/j.ad.2019.05.009

    Article  CAS  PubMed  Google Scholar 

  10. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A (1987) Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 23(11):1697–1699. https://doi.org/10.1016/0277-5379(87)90452-4

    Article  CAS  PubMed  Google Scholar 

  11. Wakuda K, Kenmotsu H, Naito T, Akamatsu H, Ono A, Shukuya T, Nakamura Y, Tsuya A, Murakami H, Takahashi T, Endo M, Nakajima T, Yamamoto N (2015) Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. Am J Clin Oncol 38(1):28–32. https://doi.org/10.1097/COC.0b013e318286907b

    Article  CAS  PubMed  Google Scholar 

  12. Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, Saijo N, Nishiwaki Y (2008) Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 113(9):2518–2523. https://doi.org/10.1002/cncr.23871

    Article  PubMed  Google Scholar 

  13. Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD (2021) Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol 32(12):1597–1607. https://doi.org/10.1016/j.annonc.2021.08.2151

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the patients and their families as well as all the investigators.

Funding

No funding was received.

Author information

Authors and Affiliations

  1. Division of Respiratory Disease, Department of Internal Medicine, The Jikei University Daisan Hospital, Tokyo, Japan

    Tsukasa Hasegawa

  2. Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

    Ryo Ariyasu, Noriko Yanagitani & Makoto Nishino

  3. Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

    Hisashi Tanaka

  4. Department of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan

    Ryota Saito

  5. Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan

    Yosuke Kawashima

  6. Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Atsushi Horiike

  7. Division of Respiratory, NTT Medical Center, Tokyo, Japan

    Toshio Sakatani

  8. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan

    Takehiro Tozuka

  9. Department of Pulmonary Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    Jun Shiihara

  10. Department of Respiratory Medicine, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

    Masafumi Saiki

  11. Department of Respiratory Medicine, Kanazawa University, Kanazawa, Japan

    Yuichi Tambo

  12. Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan

    Tomoaki Sonoda

  13. Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan

    Akito Miyazaki

  14. Department of Respiratory Medicine, Osaka Red Cross Hospital, Osaka, Japan

    Shinya Uematsu

  15. Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan

    Yuko Tsuchiya-Kawano

Authors
  1. Tsukasa Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryo Ariyasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hisashi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryota Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yosuke Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsushi Horiike
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshio Sakatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takehiro Tozuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jun Shiihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masafumi Saiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuichi Tambo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tomoaki Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Akito Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shinya Uematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yuko Tsuchiya-Kawano
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Noriko Yanagitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Makoto Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TH: Conceptualization, methodology, formal analysis, investigation, resources, data curation, writing—original draft, writing—review and editing, visualization, and project administration. RA: Conceptualization, methodology, investigation, resources, data curation, writing—review and editing, supervision, and project administration. HT, RS, YK, AH, TS, TT, JS, MS, YT, TS, AM, SU, and YT-K: Investigation, resources, data curation, and writing—review and editing. NY and MN: Writing—review and editing, supervision, and project administration.

Corresponding author

Correspondence to Ryo Ariyasu.

Ethics declarations

Conflict of interest

Tsukasa Hasegawa reports honoraria from AstraZeneca, Chugai Pharmaceutical, and Eli Lilly and Company. Ryo Ariyasu reports honoraria from AstraZeneca, Chugai Pharmaceutical, and Bristol-Myers Squibb. Hisashi Tanaka reports honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Ono Pharmaceutical, and Pfizer. Yosuke Kawashima reports honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly and Company, and Taiho Pharmaceutical. Atsushi Horiike reports receiving grants from BeiGene, Chugai Pharmaceutical, Daiichi Sankyo, Merck Sharp & Dohme, and Nippon Kayaku and honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, EP-SOGO, Kyowa Hakko Kirin, Merck Sharp & Dohme, Novartis, and Taiho Pharmaceutical. Takehiro Tozuka reports honoraria from AstraZeneca and Chugai Pharmaceutical. Yuichi Tambo reports honoraria from AstraZeneca, Chugai Pharmaceutical, Merck Sharp & Dohme, Takeda Pharmaceutical, and Taiho Pharmaceutical. Tomoaki Sonoda reports honoraria from AstraZeneca, Chugai Pharmaceutical, Kyowa Hakko Kirin, Ono Pharmaceutical, and Taiho Pharmaceutical. Shinya Uematsu reports honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly and Company, Kyowa Hakko Kirin, Nippon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical. Yuko Tsuchiya-Kawano reports honoraria from Bristol-Myers Squibb, Chugai Pharmaceutical, Kyowa Hakko Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical. Noriko Yanagitani reports honoraria from AstraZeneca, Bayer Yakuhin, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly and Company, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical and receiving payment for expert testimony from Chugai Pharmaceutical. Makoto Nishino reports honoraria from AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Nippon Kayaku, Novartis, Merck Serono, Ono Pharmaceutical, Pfizer, Takeda Pharmaceutical, and Taiho Pharmaceutical. All other authors have stated that they have no conflicts of interest.

Ethical approval

The studies included in the analysis were conducted in accordance with the Declaration of Helsinki and the good clinical practice guidelines and were approved by the institutional review board of The Jikei University Daisan Hospital.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 90 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hasegawa, T., Ariyasu, R., Tanaka, H. et al. Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02). Cancer Chemother Pharmacol 92, 29–37 (2023). https://doi.org/10.1007/s00280-023-04547-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-023-04547-2

Keywords

Search

Navigation